Should thaldex (thalidomide-dexamethasone) replace VAD (vincristine-adriamycin-dexamethasone) as induction treatment for newly diagnosed multiple myeloma? The Indian perspective

被引：0
|
作者：
Pandey, Ritwik [1 ]
Patel, Kirti M. [1 ]
Shah, Sandip A. [1 ]
Patel, Apurva A. [1 ]
机构：
[1] Gujarat Canc Res Inst, Ahmadabad, Gujarat, India
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [1] TREATMENT OF REFRACTORY MULTIPLE-MYELOMA WITH THE VINCRISTINE-ADRIAMYCIN-DEXAMETHASONE (VAD) REGIMEN
    STENZINGER, W
    BLOMKER, A
    HIDDEMANN, W
    VANDELOO, J
    BLUT, 1990, 61 (2-3): : 55 - 59
  • [2] Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
    Jimenez-Zepeda, Victor Hugo
    Dominguez-Martinez, Virginia Jeanet
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (03) : 239 - 244
  • [3] Treatment with vincristine, adriamycin and dexamethasone (VAD) on outpatient basis in multiple myeloma
    Egerer, G
    Hegenbart, U
    Wallmeier, M
    Hahn, U
    Haas, R
    Goldschmidt, H
    Hunstein, W
    BLOOD, 1996, 88 (10) : 3603 - 3603
  • [4] TREATMENT OF ADVANCED MULTIPLE-MYELOMA WITH VINCRISTINE, ADRIAMYCIN AND DEXAMETHASONE (VAD)
    LINDEMANN, A
    ZEILE, G
    MEYENBURG, W
    HERRMANN, F
    MERTELSMANN, R
    BLUT, 1986, 53 (03): : 227 - 227
  • [5] Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
    Gay, Francesca
    Hayman, Suzanne
    Lacy, Martha Q.
    Buadi, Francis
    Gertz, Morie A.
    Kumar, Shaji
    Dispenzieri, Angela
    Mikhael, Joseph R.
    Bergsagel, Leif
    Dingli, David
    Reeder, Craig B.
    Lust, John A.
    Russel, Stephen
    Roj, Vivek
    Zeldenrust, Steven R.
    Witzig, Thomas E.
    Fonseca, Rafael
    Kyle, Robert
    Greipp, Philip R.
    Stewart, A. Keith
    Rajkumar, S. Vincent
    BLOOD, 2009, 114 (22) : 1494 - 1495
  • [6] Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) as induction treatment for newly diagnosed Multiple Myeloma (MM) is associated with a lower rate of Second Primary Malignancies (SPMs) compared to Thalidomide-Dexamethasone (TD)
    Brioli, A.
    Pezzi, A.
    Muegge, L-O
    Derudas, D.
    Petti, M. C.
    Zannetti, B. A.
    Ferrara, F.
    Rocchi, S.
    Nobile, F.
    Baraldi, A.
    Musto, P.
    Lanza, F.
    Mancuso, K.
    Canepa, L.
    Catalano, L.
    Lazzaro, A.
    Pinotti, G.
    Boccadoro, M.
    Hochhaus, A.
    Cavo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 69 - 69
  • [7] EFFECT OF THALIDOMIDE-DEXAMETHASONE THERAPY ON BONE MARROW ANGIOGENESIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Ladeb, S.
    Mrad, K.
    Abdelkefi, A.
    Torjemane, L.
    Safra, I.
    Hdiji, S.
    Ben Romdhane, N.
    Mdhaffer, M.
    El Omri, H.
    Ben Othman, T.
    Ben Romdhane, K.
    Ben Abdeladhim, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 512 - 512
  • [8] Thalidomide-dexamethasone combination in symptomatic multiple myeloma: An indian experience
    Mukhopadhyay, Ashis
    Ganguly, Sanjeev
    ANNALS OF ONCOLOGY, 2004, 15 : 156 - 156
  • [9] A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
    Chim, C. S.
    Lie, A. K. W.
    Chan, E. Y. T.
    Leung, Y. Y.
    Cheung, S. C. W.
    Chan, S. Y. T.
    Liang, Raymond
    Kwong, Y. L.
    ANNALS OF HEMATOLOGY, 2010, 89 (10) : 1019 - 1027
  • [10] A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
    C. S. Chim
    A. K. W. Lie
    E. Y. T. Chan
    Y. Y. Leung
    S. C. W. Cheung
    S. Y. T. Chan
    Raymond Liang
    Y. L. Kwong
    Annals of Hematology, 2010, 89 : 1019 - 1027
12345